GSWM
CORT icon

Golden State Wealth Management’s Corcept Therapeutics CORT Stock Holding History

Golden State Wealth Management’s Portfolio CORT Stock Details CORT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-386
Closed -$13.4K – 1640
2025
Q4 		$13.4K Hold
386
– – ﹤0.01% 1023
2025
Q3 		$32.1K Hold
386
– – ﹤0.01% 788
2025
Q2 		$28.3K Buy
+386
New +$28K ﹤0.01% 790

Other funds holding CORT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ISL
Ingalls & Snyder LLC New York $3.66B AUM 57.76% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
PA
Parallel Advisors San Francisco, California $6.56B AUM 32.24% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return

Golden State Wealth Management's CORT Position: Q1 2026 in Review

Golden State Wealth Management sold out of Corcept Therapeutics (CORT) in Q1 2026, closing a stake of 386 shares — an estimated $13.4K sold.

Golden State Wealth Management first reported a position in CORT in Q2 2025 and held it in 3 quarters. The position peaked at $32.1K in Q3 2025. 352 funds tracked by Wall St. Rank hold CORT as of Q1 2026.

  • Golden State Wealth Management reported no remaining Corcept Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Golden State Wealth Management sold 386 Corcept Therapeutics shares in Q1 2026, an estimated $13.4K.
  • Golden State Wealth Management first reported a position in Corcept Therapeutics in Q2 2025 and held it in 3 quarters.
  • Golden State Wealth Management's Corcept Therapeutics position peaked at $32.1K in Q3 2025.
  • 352 funds tracked by Wall St. Rank held Corcept Therapeutics as of Q1 2026.

Based on Golden State Wealth Management's 13F filing for Q1 2026, filed 28 Apr 2026.